Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

Kazuyoshi Kawakami,1 Eri Nakamoto,1 Takashi Yokokawa,1 Kazuo Sugita,1 Yutarou Mae,1 Akane Hagino,1 Mitsukuni Suenaga,2 Nobuyuki Mizunuma,2 Sayaka Oniyama,3 Yoshiaki Machida,3 Toshiharu Yamaguchi,2 Toshihiro Hama1 1Department of Pharmacy, 2Gastroenterology Center, Cancer Institute Hospital, Japanese...

Full description

Bibliographic Details
Main Authors:	Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, Suenaga M, Mizunuma N, Oniyama S, Machida Y, Yamaguchi T, Hama T
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-04-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/patientsrsquo-self-reported-adherence-to-capecitabine-on-xelox-treatme-peer-reviewed-article-PPA

Similar Items

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Analysis of capecitabine plus oxaliplatin (xelox) combination in the management of metastatic colorectal cancer compare with fluorouracil and oxaliplatin combination (folfox)
by: Isnatin Miladiyah
Published: (2016-12-01)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
by: Suenaga M, et al.
Published: (2015-03-01)

Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
by: Andrea Queiróz Ungari, et al.
Published: (2017-10-01)

STUDY ON ADHERENCE TO CAPECITABINE AMONG PATIENTS WITH COLORECTAL CANCER AND METASTATIC BREAST CANCER
by: Adiel Goes de FIGUEIREDO JUNIOR, et al.
Published: (2014-09-01)

Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study
by: Lavery, A, et al.
Published: (2020)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
by: Yuta Ushida, et al.
Published: (2018-08-01)

A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
by: Jing Lv, et al.
Published: (2012-06-01)

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial
by: Qiu-Zhong Pan, et al.
Published: (2024-04-01)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
by: W. Si, et al.
Published: (2013-12-01)

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
by: Yan Wang, et al.
Published: (2018-06-01)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
by: Hong Zhou, et al.
Published: (2021-11-01)

Adherence and patients’ experiences with the use of capecitabine in daily practice
by: Lonneke Timmers, et al.
Published: (2016-09-01)

Acute mania due to capecitabine and oxaliplatin in a patient with metastatic colorectal cancer
by: Parikshit Padhi
Published: (2023-03-01)

Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis
by: Bradley Ashley Gue Ong, et al.
Published: (2022-04-01)

Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer
by: Xiao-Yin Zhao, et al.
Published: (2022-10-01)

Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer
by: Yoichiro Yoshida, et al.
Published: (2014-02-01)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
by: Chua Daniel TT, et al.
Published: (2011-07-01)

CAPECITABINE IN THE TREATMENT OF BRAIN METASTATIC LESION IN PATIENTS WITH BREAST CANCER
by: E. A. Moskvina, et al.
Published: (2015-04-01)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
by: Bang Soo-Mee, et al.
Published: (2006-01-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
by: Yu S, et al.
Published: (2020-10-01)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
by: Lanqi Ren, et al.
Published: (2023-08-01)

Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal carcer
by: Jungić Saša, et al.
Published: (2017-01-01)

Capecitabine in the management of colorectal cancer
by: Hirsch BR, et al.
Published: (2011-03-01)

Adherence to Capecitabine Among Patients With Gastrointestinal Cancer: A Prospective Cohort Study
by: Ahmad Khajeh-Mehrizi, et al.
Published: (2023-01-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia
by: quanfu li, et al.
Published: (2021-08-01)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
by: Zhu J, et al.
Published: (2023-02-01)

Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
by: Stephen Dyar, et al.
Published: (2011-01-01)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
by: Stephen Dyar, et al.
Published: (2011-11-01)

Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide
by: Brossart, Peter, et al.
Published: (2009-06-01)

337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI
by: Come Lepage, et al.
Published: (2020-11-01)

Oncologists’ perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer
by: Eraso Y
Published: (2019-07-01)

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
by: Jinsong Su, et al.
Published: (2019-01-01)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
by: Yeong Hak Bang, et al.
Published: (2021-03-01)

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation
by: S Ward, et al.
Published: (2003-11-01)

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
by: L Jones, et al.
Published: (2004-02-01)

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
by: Yizhang Chen, et al.
Published: (2023-10-01)